Clinical trials: Tumor Immunity, open to volunteers
Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Observational, multicenter, one-arm, non-comparative study. Data will be recorded in a retrospectively manner. The study will be based on secondary data collected from patient clinical chart completed by the doctor during routine…
- Trial name
- SIENNA (NCT06634199)
- Testing
- Durvalumab
- Where
- 22 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Fundación GECP
Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic).
- Conditions
- Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Stage IV Adenocarcinoma of the Gastroesophageal Junction
- Trial name
- NCT04221893
- Testing
- Radiation Therapy (RT)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Francisco
Colon Cancer
Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patients Undergoing Surgery for Colon Cancer - the PILDI Study
There are very few data in the literature on changes in inflammatory markers when lidocaine is administered perioperatively in patients with colorectal cancer.
- Trial name
- PILDI (NCT06923787)
- Testing
- Lidocaine
- Where
- 2 sites in Slovenia
- Volunteers
- 100 people
- Sponsor
- Institute of Oncology Ljubljana
Metastatic Malignant Solid Neoplasm, Lymphoma
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
"This phase I trial investigates the effect of radiation therapy on the immune system, specifically CD8 positive (+) T cells, in lymphoma patients receiving bridging radiation therapy before CAR T-cell infusion, and metastatic…
- Trial name
- NCT05371132
- Testing
- Positron Emission Tomography, Stereotactic Body Radiation Therapy, Zirconium Zr 89-Df-Crefmirlimab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell)
Immune Response to Immunotherapy in Lung Cancer: Study of Sputum and Blood Samples
Lung cancer is the leading cause of cancer-related death worldwide, with nearly 2.48 million cases and 1.8 million deaths in 2022.
- Trial name
- RICEPS-2 (NCT07163507)
- Testing
- Blood sample, sputum sample
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Tumor Immunity
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor
68Ga-DOTA-dPNE PET/CT imaging was performed on patients with malignant tumors to observe the binding of lesions with the tracer and evaluate the expression of CD73.
- Trial name
- NCT06844110
- Testing
- 68GA-DOTA-dPNE
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Ovarian Neoplasms, Ovarian Cancer
OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study
Ovarian cancer (OC) is one of the most lethal cancers in the world due to late-stage disease at diagnosis. Standard therapy consists of debulking surgery and chemotherapy.
- Conditions
- Ovarian Neoplasms, Ovarian Cancer, Ovarian Carcinoma, Immune Suppression
- Trial name
- RENAISSANCE (NCT06611072)
- Testing
- Bone marrow aspiration, Vena puncture, Peritoneal fluid
- Where
- Netherlands
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Gynaecologisch Oncologisch Centrum Zuid
Metastatic Breast Cancer, Breast Cancer
A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotripsy) OR pembrolizumab alone. Participants will be randomly assigned.
- Conditions
- Metastatic Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Triple Negative Breast Cancer
- Trial name
- NCT06246968
- Testing
- Pembrolizumab, Cryoablation, Histotripsy
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mesothelioma; Lung, Pancreatic Cancer
Exercise to Boost Immunity in Advanced Cancer
The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients…
- Trial name
- BICEP (NCT06310993)
- Testing
- Exercise
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Myeloma, MGUS
Intestinal Flora and Immunity in Monoclonal Gammopathy Patients
This study aims to investigate the characteristics of the gut microbiota and immune function status in patients with monoclonal gammopathy complicated by infection, and to analyze the correlation between the two.200 patients…
- Conditions
- Multiple Myeloma, MGUS, Gut Microbiota, Infections
- Trial name
- NCT06539832
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming
Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study
The goal of this clinical trial is to learn whether a high- and low-dose radiotherapy regimen followed by anti-angiogenic TKI and anti-PD-1 antibody therapy works to treat advanced metastatic colorectal cancer.
- Conditions
- Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response
- Trial name
- TRIUNITE-07 (NCT07467590)
- Testing
- High- and Low-Dose Radiotherapy, Anti-Angiogenic TKI and Anti-PD-1 Therapy
- Volunteers
- 33 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Uveal Melanoma
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) alone or in combination with Ipilimumab and Nivolumab for patients with…
- Trial name
- NCT07364474
- Testing
- Melphalan through Percutaneous Hepatic Perfusion, Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma
Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
The RADIANCE trial plans to enroll patients with chemotherapy-ineligible de novo metastatic nasopharyngeal carcinoma (AJCC 9th edition, TxNxM1).
- Trial name
- RADIANCE (NCT07756190)
- Testing
- Sintilimab, ipilimumab, Radscopal Radiotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Early Breast Cancer
Aromatherapy in the Treatment of Early Breast Cancer
Breast cancer is a major threat to women's health, and chemotherapy is one of the most important treatment method. Chemotherapy is cytotoxic , and has a positive tumor immune effect.
- Trial name
- NCT06435104
- Testing
- neoadjuvant chemotherapy, aromatherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cancer
Tumor Immunity and Cancer Recurrence Prediction Model
The purpose of this observational study is to understand the predictive effect of the laboratory-developed TIMES scoring system on the recurrence status of cancer patients who have undergone surgical tumor resection.
- Trial name
- NCT06855290
- Volunteers
- 300 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma
Evaluation of Immune Responses and Outcomes in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy
Radiation therapy is a highly effective modality for managing localized solid tumors and has become a fundamental component of treating unresectable hepatocellular carcinoma.
- Trial name
- NCT06379256
- Testing
- Photon or proton radiotherapy
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Chang Gung Memorial Hospital
Gastrointestinal Neoplasms
Interaction Between Host, Microenvironment and Immunity on Gastrointestinal Neoplasms
The primary objective: association study of characteristics of tumoral microenvironment and immunity of digestive cancers with patients' overall survival (OS).
- Trial name
- HoMING (NCT04363983)
- Testing
- Blood sampling, Liver biopsy, Stool collect
- Where
- France
- Volunteers
- 6,300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Cancer
Histidine Supplementation for Antitumor Immunity in Colorectal Cancer
The goal of this clinical study is to learn whether oral histidine supplementation may be safely used to support antitumor immune function during standard colorectal cancer treatment.
- Trial name
- NCT07577505
- Testing
- Histidine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jing-yuan Fang, MD, Ph. D
Breast Cancer
Immunomonitoring of Breast Cancer Patients During Systemic Treatment
This study aims to constitute a most complete biological collection for patients treated for localized or metastatic breast cancer (in different cohorts depending on the type of systemic treatment received), in order to describe…
- Trial name
- IMMUNE CAPTURE (NCT04925856)
- Testing
- blood sample
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- Centre Georges Francois Leclerc
Solid Cancer
An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours
This is an exploratory clinical study evaluating the safety, tolerability, immune response and preliminary efficacy of LM103 Injection in combination with PD-1 in patients with advanced solid tumours.
- Trial name
- NCT06697665
- Testing
- LM103
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.